Amryt Pharma PLC (NASDAQ:AMYT) (LON:AMYT) CEO Joe Wiley tells Proactive the group has raised $40M from leading biotech investors in a private placement, with a tranche of the proceeds being used to in-license or invest in rare disease technologies.
Wiley says investors include Stonepine Capital, Aquilo Capital Management, Amati Global Investors, Athyrium Capital Management, and Highbridge Capital Management. What's more, the firm has received marketing approval from the authorities in Brazil for its specialist cholesterol drug Lojuxta.
